Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years

(1) Background: Altered levels of autoantibodies (aab) and their networks have been identified as biomarkers for various diseases. Neovascular age-related macular degeneration (nAMD) is a leading cause for central vision loss worldwide with highly variable inter- and intraindividual disease courses....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michelle Prasuhn, Caroline Hillers, Felix Rommel, Gabriela Riemekasten, Harald Heidecke, Khaled Nassar, Mahdy Ranjbar, Salvatore Grisanti, Aysegül Tura
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	autoantibodies age-related macular degeneration biomarkers AT1-receptor PAR1 VEGF-A Medicine R
Acceso en línea:	https://doaj.org/article/b0555f88cd534b928e5f44589455b39c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b0555f88cd534b928e5f44589455b39c
record_format	dspace
spelling	oai:doaj.org-article:b0555f88cd534b928e5f44589455b39c2021-11-25T18:08:01ZSpecific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years10.3390/jpm111112072075-4426https://doaj.org/article/b0555f88cd534b928e5f44589455b39c2021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1207https://doaj.org/toc/2075-4426(1) Background: Altered levels of autoantibodies (aab) and their networks have been identified as biomarkers for various diseases. Neovascular age-related macular degeneration (nAMD) is a leading cause for central vision loss worldwide with highly variable inter- and intraindividual disease courses. Certain aab networks could help in daily routine to identify patients with a high disease activity who need to be visited and treated more regularly. (2) Methods: We analyzed levels of aab against Angiotensin II receptor type 1 (AT1-receptor), Protease-activated receptors (PAR1), vascular endothelial growth factor (VEGF) -A, VEGF-B, and VEGF-receptor 2 in sera of 164 nAMD patients. In a follow-up period of five years, we evaluated changes in functional and morphological characteristics. Using correlation analyses, multiple regression models, and receiver operator characteristics, we assessed whether the five aab have a clinical significance as biomarkers that correspond to the clinical properties. (3) Results: Neither the analyzed aab individually nor taken together as a network showed statistically significant results that would allow us to draw conclusions on the clinical five-year course in nAMD patients. (4) Conclusions: The five aab that we analyzed do not correspond to the clinical five-year course of nAMD patients. However, larger, prospective studies should reevaluate different and more aab to gain deeper insights.Michelle PrasuhnCaroline HillersFelix RommelGabriela RiemekastenHarald HeideckeKhaled NassarMahdy RanjbarSalvatore GrisantiAysegül TuraMDPI AGarticleautoantibodiesage-related macular degenerationbiomarkersAT1-receptorPAR1VEGF-AMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1207, p 1207 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	autoantibodies age-related macular degeneration biomarkers AT1-receptor PAR1 VEGF-A Medicine R
spellingShingle	autoantibodies age-related macular degeneration biomarkers AT1-receptor PAR1 VEGF-A Medicine R Michelle Prasuhn Caroline Hillers Felix Rommel Gabriela Riemekasten Harald Heidecke Khaled Nassar Mahdy Ranjbar Salvatore Grisanti Aysegül Tura Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years
description	(1) Background: Altered levels of autoantibodies (aab) and their networks have been identified as biomarkers for various diseases. Neovascular age-related macular degeneration (nAMD) is a leading cause for central vision loss worldwide with highly variable inter- and intraindividual disease courses. Certain aab networks could help in daily routine to identify patients with a high disease activity who need to be visited and treated more regularly. (2) Methods: We analyzed levels of aab against Angiotensin II receptor type 1 (AT1-receptor), Protease-activated receptors (PAR1), vascular endothelial growth factor (VEGF) -A, VEGF-B, and VEGF-receptor 2 in sera of 164 nAMD patients. In a follow-up period of five years, we evaluated changes in functional and morphological characteristics. Using correlation analyses, multiple regression models, and receiver operator characteristics, we assessed whether the five aab have a clinical significance as biomarkers that correspond to the clinical properties. (3) Results: Neither the analyzed aab individually nor taken together as a network showed statistically significant results that would allow us to draw conclusions on the clinical five-year course in nAMD patients. (4) Conclusions: The five aab that we analyzed do not correspond to the clinical five-year course of nAMD patients. However, larger, prospective studies should reevaluate different and more aab to gain deeper insights.
format	article
author	Michelle Prasuhn Caroline Hillers Felix Rommel Gabriela Riemekasten Harald Heidecke Khaled Nassar Mahdy Ranjbar Salvatore Grisanti Aysegül Tura
author_facet	Michelle Prasuhn Caroline Hillers Felix Rommel Gabriela Riemekasten Harald Heidecke Khaled Nassar Mahdy Ranjbar Salvatore Grisanti Aysegül Tura
author_sort	Michelle Prasuhn
title	Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years
title_short	Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years
title_full	Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years
title_fullStr	Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years
title_full_unstemmed	Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years
title_sort	specific autoantibodies in neovascular age-related macular degeneration: evaluation of morphological and functional progression over five years
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b0555f88cd534b928e5f44589455b39c
work_keys_str_mv	AT michelleprasuhn specificautoantibodiesinneovascularagerelatedmaculardegenerationevaluationofmorphologicalandfunctionalprogressionoverfiveyears AT carolinehillers specificautoantibodiesinneovascularagerelatedmaculardegenerationevaluationofmorphologicalandfunctionalprogressionoverfiveyears AT felixrommel specificautoantibodiesinneovascularagerelatedmaculardegenerationevaluationofmorphologicalandfunctionalprogressionoverfiveyears AT gabrielariemekasten specificautoantibodiesinneovascularagerelatedmaculardegenerationevaluationofmorphologicalandfunctionalprogressionoverfiveyears AT haraldheidecke specificautoantibodiesinneovascularagerelatedmaculardegenerationevaluationofmorphologicalandfunctionalprogressionoverfiveyears AT khalednassar specificautoantibodiesinneovascularagerelatedmaculardegenerationevaluationofmorphologicalandfunctionalprogressionoverfiveyears AT mahdyranjbar specificautoantibodiesinneovascularagerelatedmaculardegenerationevaluationofmorphologicalandfunctionalprogressionoverfiveyears AT salvatoregrisanti specificautoantibodiesinneovascularagerelatedmaculardegenerationevaluationofmorphologicalandfunctionalprogressionoverfiveyears AT aysegultura specificautoantibodiesinneovascularagerelatedmaculardegenerationevaluationofmorphologicalandfunctionalprogressionoverfiveyears
_version_	1718411578772029440

Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years

Ejemplares similares